As the popularity of Ozempic, Victoza, Wegovy and other GLP-1 agents continues to increase, … more
If you take Ozempic or Zepbound for diabetes or weight loss, you can make your wallet lighter. From 2024 to 2025, the scope of insurance coverage of Ozempic including Semaglutide GOODRX analysis Insight and technology of management market. This means that additional 1.1 million people were no longer able to have such a range of glucagon -like peptide -1 receptor agents. During the same period, the number of people without insurance coverage for Zepbound, another GLP-1 receptor agent, increased 14%, which means that other 4.9 million others did not fit the insurance coverage for Zepbound.
Demand for Ozempic, Zepbound and other GLP-1 agents continues to increase despite prices.
Therefore, demand continues to increase while the scope of insurance coverage to these drugs is decreasing. GOODRX other analytics set According to data from representative samples nationwide for about 50,000 pharmacies across the United States, fillings for Zepbound have increased by 300% since early 2024. During the same period, the charging speed of Ozempic has doubled. The popularity of the GLP-1 receptor agent continued to grow even after it turned out that the weight loss was quite fast when it was taken.
Now Zepbound, Wegovy and Saxenda are officially approved for weight loss in the Food and Drug Administration, and FDA approval for Ozempic, Mounjaro and Victoza is especially especially especially in type 2 diabetes. It is for treatment. However, how many tiktok likes, because of the popularity of all these drugs, taking people to lose weight.
Of course, taking GLP-1 agents has no potential disadvantages. Already written Forbes About so much effect called “Ozempic Butt” and “Wegovy Finger.” There are also more serious side effects such as the president. Moreover, since the research has not yet been extended for decades, it is not completely clear what long -term effects are by taking these drugs every week.
In addition, the drug is not cheap without insurance to offset the price. The list price of Ozempic Injection Pen is $ 997.58. According to the manufacturer, according to NOVO NORDISK,. meantime, Lily list The price of Zepbound is $ 1,086.37 per charging. The most common way to take such a drug is through an injection per week. And when you start this drug, the plan is to continue to take and take it. Not all weight loss is lost immediately after the drug is stopped, but most of the weight is not lost. This means that these costs can be added faster than $ 1,300 a month. Therefore, assuming that health insurance has health insurance, it is reasonable to make sure that health insurance can cover some of all these costs.
The scope of insurance coverage for ozempic, zepbound and other GLP-1 agents is complex and changes
Few people describe health insurance as simple things. Finding out that certain insurance policy does not cover it can only be as complicated to find out the conspiracy of the TV series. lost. When you try to use health insurance to pay something, it’s not different from buying a Ryan Reynolds pillow case in Amazon. Everyone needs to see the price clearly, can afford it every night, and only know the amount of Reynold’s chest that you want to see every night. GOODRX analysis has stopped the scope of insurance coverage for GLP-1 receptor agents into three categories:
- No application range: This means you are alone to find a way to pay medicine.
- Limited application scope: The insurance company imposes a kind of requirements that can be satisfied before insurance application is possible. You may need to get “prior approval.” In other words, the insurance company reviews your case, says “yes” or “nay”, or try another treatment first. All of this can be painful where you know. Therefore, people can feel frustrated and continue to pay for the drug itself.
- Scope of application without restrictions: This is a kind of holy grail for insurance policy holders. Insurance just proceeded to pay the drug. Of course, this does not necessarily mean that insurance can make you easily. It may still not cover the entire price. You may also need to meet the deductions first before the insurance coverage starts completely.
Therefore, since 2024, ZEPBOUND has increased the proportion of people with unlimited insurance coverage from 9%to 13%. At the same time, the proportion of limited applications dropped from 73%to 66%. The net has lost 14%of insurance coverage mentioned earlier.
The two drugs, which contain another GLP-1 receptor agonist, Lira Gluten, have also reduced the scope of commercial insurance coverage. The proportion of people without insurance coverage for Victoza has increased by 92%, which is 30 million since 2024. Meanwhile, the percentage of SAXENDA is 47%or 30 million. At the same time, the number of people who had to deal with the limit on Victoza’s insurance coverage increased by 22%. New availability GEnerer Liraglutide can trigger this change because at least 9.5 million people have been reported on the general form in 2025. However, up to 32%of the number of people with restrictions on the scope of insurance coverage, everything was not wrong in the case of general Liraglutide.
At the same time, the approach to Wegovy was actually benefited by the fact that one of the drugs that the FDA actually approved by weight loss was a bit more insurance coverage. Compared to 2024, the proportion of people with no limitations in the coverage increased from 14.2%to 14.6%, which benefited at least 600,000 people, and the proportion of those with limited application scope was 67%to 71%. This was better for insurance coverage for more than 7 million potential users of Wegovy in 2025. However, more than 82% of people have faced limitations on insurance coverage. WegovyZepbound and Saxenda, three GLP-1 agonist FDAs were approved for weight loss.
The scope of insurance coverage for Ozempic, Zepbound and other GLP-1 agents will grow.
Unitedhealthcare, the largest health insurance company in the United States, dealing with more than 50 million lives … more
It is not surprising that insurance plans have imposed more restrictions on the insurance as the use of GLP-1 agents increases. After all, many insurance companies are for -profit, which means that making profits is probably quite high in what they want to do. Then there is an insurance company that is openly traded, and the insurance company wants to make money for many investors as well as by itself.
Insurance companies across the United States have been successful in achieving these goals. 2023, National Insurance Commissioner Association 10 years snapshot provided Total financial results in the US health insurance industry. “The health insurance industry continued to profitable as its net profit was reported to have increased to nearly $ 25 billion (3%), but the profitability trend was reported to have decreased to 2.2%in 2023 compared to net profit.
In 2022, $ 24 billion and 2.4%of profit margins are 2.4%. “Therefore, it does not seem to be struggling to achieve its purpose.
Nevertheless, insurance companies can negatively affect the scope of the GLP-1 receptor agent as a threat to profit. Assuming that a new weight is within a healthy range, it can be argued that people’s help to lose weight can save other medical costs. The problem is that if the insurance company changes the insurance policy, especially when changing jobs every few years, the insurance company does not necessarily have to see long -term financial benefits.
This is a problem that will not disappear at least until the price of the GLP-1 agent falls. Inputting more GLP-1 agents in the market, especially in general markets, can eventually drop prices. But if you are interested in taking Ozempic, Zepbound or other GLP-1 agents, you can first check your insurance plan. It can be a bit light on the coverage.
